Eli Lilly and Company (NYSE: LLY), a United States-based pharmaceutical company, announced on Thursday that its board of directors has named Gabrielle Sulzberger as its new director, effective 25 January 2021.
Sulzberger will serve on both the company's Audit Committee and Ethics and Compliance Committee.
Sulzberger serves as a strategic advisor to Two Sigma Impact. She has held the position of a general partner of Rustic Canyon/Fontis Partners LP. She was also a principal of several private equity funds during her 30 plus-years of experience in financial services and chief financial officer of several public and private companies. Presently, Sulzberger is also a member of the board of directors for various companies including MasterCard Incorporated, Brixmor Property Group Inc, Cerevel Therapeutics Holdings Inc, and several other private companies and philanthropic organisations. She has held the position of chairman of the board of Whole Foods and audit committee chair for Whole Foods.
Biller Named to Rome Therapeutics Board of Directors
Beck Named Chief Financial Officer at 4D Pharma
Gyroscope Therapeutics names Jessica Stitt as CFO
Campanelli Named to Slayback Board of Directors
Zhang Named Chief Medical Officer at InnoCare
The University of Health Sciences and Pharmacy in St Louis names new president
New COVID-19 virus variant discovered in New York City and Northeast US
NovellusDx Establishes Fore Biotherapeutics US as its Operating company in the United States
Dhingra Named Chairman of the Board of Directors at Lava Therapeutics